Autolus Therapeutics (NASDAQ:AUTL) Trading Up 5.4% – Should You Buy?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price traded up 5.4% during trading on Friday . The stock traded as high as $4.33 and last traded at $4.33. 105,822 shares traded hands during trading, a decline of 92% from the average session volume of 1,354,945 shares. The stock had previously closed at $4.11.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.70.

Autolus Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The company’s 50-day moving average price is $3.88 and its 200-day moving average price is $4.17. The company has a market cap of $1.10 billion, a P/E ratio of -3.57 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC acquired a new position in Autolus Therapeutics during the first quarter worth $78,765,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the last quarter. Great Point Partners LLC grew its holdings in shares of Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after acquiring an additional 2,275,000 shares in the last quarter. Affinity Asset Advisors LLC increased its position in shares of Autolus Therapeutics by 117.7% in the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock valued at $21,532,000 after acquiring an additional 1,824,592 shares during the last quarter. Finally, Armistice Capital LLC raised its holdings in Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.